LDL Lowering in Peripheral Arterial Disease

Are There Benefits Beyond Reducing Cardiovascular Morbidity and Mortality?

Amy W Pollak; Christopher M Kramer

Disclosures

Clin Lipidology. 2012;7(2):141-149. 

In This Article

Conclusion

There is a clear reduction in cardiovascular events with statin therapy and LDL lowering in patients with PAD. Given the symptoms of leg discomfort and reduction in exercise capacity in patients with PAD, there remains strong interest in medical therapy aimed at improving these symptoms. Although no individual trial has shown an increase in peak treadmill-walking time with statin therapy, several trials demonstrate a reduction in claudication symptoms. The Cochrane meta-analysis found an improvement in 6-min walk distance with statins, which may be more reflective of activities of daily living than an exercise treadmill test.[11] Clinical trials of statin therapy and exercise performance are influenced by the baseline LDL level, pre-existing treatment with statin drugs and study duration. Insight into the pleiotropic effects of statins and the complex pathophysiology of claudication has provided new avenues to understand how exercise capacity can be improved in PAD.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....